Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 190)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 390.080
Gesamt: 390.080
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
6,7700
USD
-4,24 %
-0,3000 USD
Letzter Kurs 18.05.24 NYSE
Neuigkeiten
17.05.24 · Accesswire  |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9300 | -17,52 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
FeedbackIs it Time to Say Goodbye to Valeant Pharmaceuticals Intl Inc.?
https://www.fool.ca/2017/10/12/is-it-time-to-say-goodbye-to-…...
...
https://fintel.io/so/us/vrx
Nur damit der Link nicht zu weit weg verschwindet.
Nur damit der Link nicht zu weit weg verschwindet.
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrat...
https://ih.advfn.com/p.php?pid=nmona&article=75848305
...
Dr. Lawrence Green will be presenting additional information about SILIQ during a product theatre titled, "A New Mechanism of Action in the Treatment of Moderate-to-Severe Plaque Psoriasis" on Thursday, October 12th at 1pm – 2pm PT.
"I am pleased to see the durable efficacy of SILIQ demonstrated through these additional findings," said Joseph C. Papa, chairman and CEO, Valeant. "This dermatologic innovation has been shown to not only provide relief for many patients who suffer from moderate-to-severe plaque psoriasis, but also had an overall positive impact on the quality of life of these patients."
...
https://ih.advfn.com/p.php?pid=nmona&article=75848305
...
Dr. Lawrence Green will be presenting additional information about SILIQ during a product theatre titled, "A New Mechanism of Action in the Treatment of Moderate-to-Severe Plaque Psoriasis" on Thursday, October 12th at 1pm – 2pm PT.
"I am pleased to see the durable efficacy of SILIQ demonstrated through these additional findings," said Joseph C. Papa, chairman and CEO, Valeant. "This dermatologic innovation has been shown to not only provide relief for many patients who suffer from moderate-to-severe plaque psoriasis, but also had an overall positive impact on the quality of life of these patients."
...
Trading Spotlight
Antwort auf Beitrag Nr.: 55.934.756 von marty44 am 12.10.17 09:19:38https://www.globalacademycme.com/conferences/lvd/agenda
Ich will mal hoffen, daß VRX im Nachgang oder parallel ein paar Poster der Studienergebnisse publiziert. Das könnte dann Montag sein, so ich hoffe.
Ich will mal hoffen, daß VRX im Nachgang oder parallel ein paar Poster der Studienergebnisse publiziert. Das könnte dann Montag sein, so ich hoffe.
ORTHO DERMATOLOGICS TO PRESENT SILIQ™ (BRODALUMAB) INJECTION DATA FROM PIVOTOL PHASE III CLINICAL TRIAL AT FALL CLINICAL DERMATOLOGY CONFERENCE
http://ortho-dermatologics.com/about-us/press-room/
RALEIGH, N.C., Oct. 10, 2017 – Ortho Dermatologics, one of the largest prescription dermatology businesses in the world, announced today that results from the SILIQ™ pivotal Phase 3 long-term extension study will be presented at the Fall Clinical Dermatology Conference in Las Vegas on October 12 – 15, 2017. In total, six new abstracts will be presented, including new data about the long-term efficacy of SILIQ, the efficacy of SILIQ in ustekinumab-naïve and -experienced patients with moderate-to-severe plaque psoriasis, as well as the impact of SILIQ treatment on health-related quality of life.
http://ortho-dermatologics.com/wp-content/uploads/0173-Fall-…
http://ortho-dermatologics.com/about-us/press-room/
RALEIGH, N.C., Oct. 10, 2017 – Ortho Dermatologics, one of the largest prescription dermatology businesses in the world, announced today that results from the SILIQ™ pivotal Phase 3 long-term extension study will be presented at the Fall Clinical Dermatology Conference in Las Vegas on October 12 – 15, 2017. In total, six new abstracts will be presented, including new data about the long-term efficacy of SILIQ, the efficacy of SILIQ in ustekinumab-naïve and -experienced patients with moderate-to-severe plaque psoriasis, as well as the impact of SILIQ treatment on health-related quality of life.
http://ortho-dermatologics.com/wp-content/uploads/0173-Fall-…
Earnings Preview: Valeant Pharmaceuticals
https://seekingalpha.com/article/4112918-earnings-preview-va…
Antwort auf Beitrag Nr.: 55.902.400 von marty44 am 07.10.17 16:15:55
Komplikationen.
Klappt nicht immer.
Komplikationen.
Klappt nicht immer.
GI Survey Bodes Well for Valeant (VRX), Less So For Allergan (AGN) - Deutsche Bank
https://www.streetinsider.com/Analyst+Comments/GI+Survey+Bod… 
Durchsuchen
Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
